DYADIC INTERNATIONAL INC. - COMMON STOCK

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

21 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets

12 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

04 Nov 2024 15:30:00 By Nasdaq GlobeNewswire

Dyadic Expands Global Presence with Participation in Key Industry Events

09 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

23 Sep 2024 08:50:55 By Nasdaq GlobeNewswire

Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

13 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

30 Jul 2024 15:00:00 By Nasdaq GlobeNewswire

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

28 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend Industry Events in June

30 May 2024 15:30:00 By Nasdaq GlobeNewswire

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

14 May 2024 15:00:00 By Nasdaq GlobeNewswire

Dyadic to Attend Industry and Investor Events in May

08 May 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

30 Apr 2024 15:30:00 By Nasdaq GlobeNewswire

Dyadic Reports 2023 Full Year Results and Recent Company Progress

28 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Dyadic Announces Change in Board and Management Leadership Roles

28 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend Industry Events in April

27 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

26 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

21 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

14 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

11 Mar 2024 08:57:14 By Nasdaq GlobeNewswire

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

11 Mar 2024 07:30:00 By Nasdaq GlobeNewswire